News Column

Xiamen University Reports Findings in Drug Delivery Systems (Mitomycin C-Soybean Phosphatidylcholine Complex-Loaded Self-Assembled PEG-Lipid-PLA...

September 10, 2014



Xiamen University Reports Findings in Drug Delivery Systems (Mitomycin C-Soybean Phosphatidylcholine Complex-Loaded Self-Assembled PEG-Lipid-PLA Hybrid Nanoparticles for Targeted Drug Delivery and Dual-Controlled Drug Release)

By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Drugs and Therapies have been presented. According to news originating from Xiamen, People's Republic of China, by NewsRx correspondents, research stated, "Most present drug phospholipid delivery systems were based on a water-insoluble drug phospholipid complex but rarely water-soluble drug phospholipid complex. Mitomycin C (MMC) is a water-soluble anticancer drug extensively used in first-line chemotherapy but is limited by its poor aqueous stability in vitro, rapid elimination from the body, and lack of target specificity."

Our news journalists obtained a quote from the research from Xiamen University, "In this article, we report the MMC-soybean phosphatidylcholine complex-loaded PEG-lipid-PLA hybrid nanoparticles (NPs) with Folate (FA) functionalization (FA-PEG-PE-PLA NPs@MMC-SPC) for targeted drug delivery and dual-controlled drug release. FA-PEG-PE-PLA NPs@MMC-SPC comprise a hydrophobic core (PLA) loaded with MMC-SPC, an amphiphilic lipid interface layer (PE), a hydrophilic shell (PEG), and a targeting ligand (FA) on the surface, with a spherical shape, a nanoscaled particle size, and high drug encapsulation efficiency of almost 95%. The advantage of the new drug delivery systems is the early phase controlled drug release by the drug phospholipid complex and the late-phase controlled drug release by the pH-sensitive polymer lipid hybrid NPs. In vitro cytotoxicity and hemolysis assays demonstrated that the drug carriers were cytocompatible and hemocompatible. The pharmacokinetics study in rats showed that FA-PEG-PE-PLA NPs@MMC-SPC significantly prolonged the blood circulation time compared to that of the free MMC. More importantly, FA-PEG-PE-PLA NPs@MMC-SPC presented the enhanced cell uptake/cytotoxicity in vitro and superior tumor accumulation/therapeutic efficacy in vivo while reducing the systemic toxicity. A significant accumulation of MMC in the nuclei as the site of MMC action achieved in FA-PEG-PE-PLA NPs@MMC-SPC made them ideal for MMC drug delivery."

According to the news editors, the research concluded: "This study may provide an effective strategy for the design and development of the water-soluble drug phospholipid complex-based targeted drug delivery and sustained/controlled drug release."

For more information on this research see: Mitomycin C-Soybean Phosphatidylcholine Complex-Loaded Self-Assembled PEG-Lipid-PLA Hybrid Nanoparticles for Targeted Drug Delivery and Dual-Controlled Drug Release. Molecular Pharmaceutics, 2014;11(8):2915-2927. Molecular Pharmaceutics can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)

The news correspondents report that additional information may be obtained from Y. Li, Xiamen University, Dept. of Chem, Coll Chem & Chem Engn, Xiamen 361005, People's Republic of China. Additional authors for this research include H.J. Wu, X.R. Yang, M.M. Jia, Y.X. Li, Y. Huang, J.Y. Lin, S.C. Wu and Z.Q. Hou (see also Drugs and Therapies).

Keywords for this news article include: Xiamen, People's Republic of China, Asia, Antibiotics - Antineoplastics, Drug Delivery Systems, Drugs, Drugs and Therapies, Emerging Technologies, Indolequinones, Mitomycins, Nanoparticle, Nanotechnology, Pharmaceuticals, Therapy

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters